SGMT
NASDAQSagimet Biosciences Inc.
News25/Ratings12
News · 26 weeks42-33%
2025-10-262026-04-19
Mix2690d
- Insider8(31%)
- Other7(27%)
- SEC Filings7(27%)
- Analyst3(12%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form DEF 14A filed by Sagimet Biosciences Inc.DEF 14A - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerSAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. "We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development
- PRSagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada. MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium presentation details: Poster Title:Reduction of plasma glycine- and taurine-conjugated bile acids
- ANALYSTRodman & Renshaw initiated coverage on Sagimet Biosciences with a new price targetRodman & Renshaw initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $28.00
- SECSEC Form S-8 filed by Sagimet Biosciences Inc.S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSEC Form S-8 filed by Sagimet Biosciences Inc.S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSEC Form 10-K filed by Sagimet Biosciences Inc.10-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatesCompleted Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, exclusive license to TAPI's innovative forms of resmetirom active pharmaceutical ingredients (API) First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis China's National Medical Products Administration (NMPA) accepted Ascletis' New Drug Application (NDA) for denifanstat for the
- PRSagimet Biosciences Announces Participation in Three Upcoming Investor ConferencesSAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences. TD Cowen 46th Annual Health Care Conference in Boston, MA, on March 2, 2026, with a fireside chat at 1:10pm ET (link here).Leerink Global Healthcare Conference in Miami, FL, on March 9, 2026, with a fireside chat at 1pm ET (link here).The Citizens Life Sciences Conference in Miami, FL, on March 10, 2026, with a fireside chat at 10:45am ET. The TD Cowen and Leerink fireside chats wi
- INSIDERChief Legal & Admin. Officer Rozek Elizabeth was granted 44,000 units of Series A Common Stock, increasing direct ownership by 23% to 234,959 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERChief Medical Officer Martins Eduardo Bruno was granted 44,000 units of Series A Common Stock, increasing direct ownership by 43% to 147,296 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERPresident & CEO Happel David was granted 128,000 units of Series A Common Stock, increasing direct ownership by 19% to 805,621 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERChief Financial Officer Chauche Thierry was granted 44,000 units of Series A Common Stock, increasing direct ownership by 280% to 59,688 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERPresident & CEO Happel David sold $64,865 worth of Series A Common Stock (12,101 units at $5.36), decreasing direct ownership by 2% to 677,621 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERChief Financial Officer Chauche Thierry sold $7,033 worth of Series A Common Stock (1,312 units at $5.36), decreasing direct ownership by 8% to 15,688 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERChief Medical Officer Martins Eduardo Bruno sold $19,511 worth of Series A Common Stock (3,640 units at $5.36), decreasing direct ownership by 3% to 103,296 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERChief Legal & Admin. Officer Rozek Elizabeth sold $14,054 worth of Series A Common Stock (2,622 units at $5.36), decreasing direct ownership by 1% to 190,959 units (SEC Form 4)4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- PRSagimet Biosciences Announces Participation in Two Upcoming Investor ConferencesSAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY, on February 11, 2026, with a fireside chat at 10am ET (link here).Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, with a fireside chat at 9:20am ET (link here). The Guggenheim and Oppenheimer fireside chats will be available in the Investors & Media section of Sagimet's website at www.
- ANALYSTGuggenheim initiated coverage on Sagimet Biosciences with a new price targetGuggenheim initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $27.00
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe AcneSAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 for acne in China and by Sagimet for MASH in the rest of the world. Sagimet has granted an exclusive
- PRAscletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of acne - New Drug Application for denifanstat (ASC40) for acne was recently accepted by the China National Medical Products Administration HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase I
- ANALYSTBarclays initiated coverage on Sagimet Biosciences with a new price targetBarclays initiated coverage of Sagimet Biosciences with a rating of Equal Weight and set a new price target of $8.00